Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifampridine Phosphate Withdrawal Study in LEMS
NCT02970162Phase 3Completed
- Start
- Nov 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lambert-Eaton myasthenic syndrome (LEMS) comparing Amifampridine Phosphate with Placebo (2 arms). Primary endpoints: Quantitative Myasthenia Gravis Score at Day 4 and Subject Global Impression Score at Day 4. Started Nov 2016; status: completed.
02
Drugs
amifampridine
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on NCT02970162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970162.